Janssen and Hanmi Pharmaceutical will start a global phase-2 clinical trial on HM12525A, an investigational drug to treat obesity and diabetes simultaneously. The study will assess the drug’s effectiveness in 440 seriously obese patients.
The U.S. website clinicaltrials.gov updated Janssen’s study on the medication on Wednesday.
HM12525A is a drug candidate that helps reduce weight and blood sugar at the same time. In November 2015, Hanmi Pharm licensed out to Janssen rights to develop and sell the drug in the world, except for China and Korea.
“Janssen and Hanmi will make every effort to commercialize HM12525A as soon as possible, to provide a new therapy option for patients suffering from obesity and diabetes,” an official at Hanmi Pharm said.
<© Korea Biomedical Review, All rights reserved.>